852 – Efficacy and Safety of B/F/TAF in Children and Infants Aged ≥1 Month, Weighing 3 to <25 kg: Week 24
Background Treatment options for children with HIV are limited. Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is a well-tolerated antiretroviral therapy (ART) with a high barrier to resistance approved in the US for children weighing ≥14 kg and in other countries for children ≥25 kg. However, data on its use in younger children are limited. We present efficacy and safety outcomes for…